Press Releases

December 26, 2018
Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership
December 19, 2018
Immunomedics to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 06, 2018
Immunomedics Provides Clinical Updates On Breast Cancer Programs With Sacituzumab Govitecan
November 08, 2018
Immunomedics Announces Presentation At Upcoming Healthcare Conferences
November 07, 2018
Immunomedics Announces First Quarter Fiscal 2019 Results And Provides Corporate Update
Immunomedics Expands Clinical Collaboration With Astrazeneca To Include Metastatic Non-Small Cell Lung Cancer
October 31, 2018
Immunomedics to report first quarter fiscal 2019 results and host conference call and webcast on November 7, 2018
September 12, 2018
Immunomedics and Samsung Biologics Announce Strategic Manufacturing Partnership
August 28, 2018
Immunomedics Announces Participation in Upcoming Healthcare Conferences
August 23, 2018
Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update
August 16, 2018
Immunomedics to report fourth quarter and fiscal year 2018 results and host conference call and webcast on August 23, 2018
July 23, 2018
Immunomedics announces clinical collaboration with AstraZeneca in first-line triple-negative breast and urothelial cancers
July 18, 2018
FDA accepts biologics license application for filing and grants priority review for sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer
June 13, 2018
Immunomedics announces pricing of public offering of common stock
June 11, 2018
Immunomedics announces proposed public offering of common stock
June 04, 2018
Immunomedics provides business update at the ASCO 2018 investor event
June 03, 2018
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer
June 01, 2018
Immunomedics announces pivotal study of sacituzumab govitecan in patients with locally advanced or metastatic urothelial cancer
May 30, 2018
Immunomedics to present at Jefferies 2018 Global Healthcare Conference
May 21, 2018
Immunomedics submits biologics license application for sacituzumab govitecan to the U.S. Food and Drug Administration
May 16, 2018
Immunomedics Announces Promising Data Of Sacituzumab Govitecan In Estrogen Receptor-Positive Metastatic Breast Cancer
May 09, 2018
Immunomedics announces third quarter fiscal 2018 results and provides corporate update
May 02, 2018
Immunomedics to report third quarter fiscal 2018 results and host conference call and webcast
April 25, 2018
Immunomedics announces oral presentation of sacituzumab govitecan in hormone receptor-positive (HR+) metastatic breast cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) annual meeting
April 09, 2018
Immunomedics appoints Dr. Robert Iannone head of Research & Development and Chief Medical Officer
March 05, 2018
Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference
February 15, 2018
Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference
February 08, 2018
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
February 06, 2018
Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018
January 11, 2018
Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer
January 08, 2018
Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million
January 04, 2018
Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference